Literature DB >> 15464058

Antitumor effect of avermectins.

Victor A Drinyaev1, Vladimir A Mosin, Elena B Kruglyak, Tamara S Novik, Tatiana S Sterlina, Natalia V Ermakova, Ludmila N Kublik, Maria Kh Levitman, Vera V Shaposhnikova, Yuri N Korystov.   

Abstract

The effect of a mixture of naturally occurring aversectin C and avermectin B(1) on the growth of ascites and solid experimental tumors of mice was studied. It was shown for the first time that avermectins possess a pronounced antitumor action. When added at nontoxic doses, they significantly suppressed the growth of ascites Ehrlich carcinoma and P388 lympholeukemia and solid Ehrlich and 755 carcinomata. With some administration regimens, avermectins suppressed the tumor growth by 70-80%. Avermectins were most effective when injected intraperitoneally. It was also shown that avermectins enhanced the vincristine-induced suppression of the growth of Ehrlich carcinoma, melanoma B16, and P388 lympholeukemia. Avermectins produced this effect only when injected after vincristine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15464058     DOI: 10.1016/j.ejphar.2004.08.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.

Authors:  Mandy Juarez; Alejandro Schcolnik-Cabrera; Alfonso Dueñas-Gonzalez
Journal:  Am J Cancer Res       Date:  2018-02-01       Impact factor: 6.166

Review 2.  Astonishing diversity of natural surfactants: 2. Polyether glycosidic ionophores and macrocyclic glycosides.

Authors:  Valery M Dembitsky
Journal:  Lipids       Date:  2005-03       Impact factor: 1.880

3.  Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine.

Authors:  Na Li; Huanni Li; Ya Wang; Lanqin Cao; Xianquan Zhan
Journal:  EPMA J       Date:  2020-10-10       Impact factor: 6.543

4.  The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer.

Authors:  Alice Melotti; Christophe Mas; Monika Kuciak; Aiala Lorente-Trigos; Isabel Borges; Ariel Ruiz i Altaba
Journal:  EMBO Mol Med       Date:  2014-10       Impact factor: 12.137

5.  Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer.

Authors:  Sho Nambara; Takaaki Masuda; Miki Nishio; Shotaro Kuramitsu; Taro Tobo; Yushi Ogawa; Qingjiang Hu; Tomohiro Iguchi; Yousuke Kuroda; Shuhei Ito; Hidetoshi Eguchi; Keishi Sugimachi; Hiroshi Saeki; Eiji Oki; Yoshihiko Maehara; Akira Suzuki; Koshi Mimori
Journal:  Oncotarget       Date:  2017-11-21

6.  Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation.

Authors:  Rafael R M Madrid; Patrick D Mathews; Ana C M F Patta; Anai P Gonzales-Flores; Carlos A B Ramirez; Vera L S Rigoni; Marcos Tavares-Dias; Omar Mertins
Journal:  Heliyon       Date:  2020-12-31

7.  Regression of bovine cutaneous papillomas via ivermectin-induced immunostimulant and oxidative stress.

Authors:  AbdulRahman A Saied
Journal:  J Adv Vet Anim Res       Date:  2021-07-20

8.  Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.

Authors:  Dobrin Draganov; Sailesh Gopalakrishna-Pillai; Yun-Ru Chen; Neta Zuckerman; Sara Moeller; Carrie Wang; David Ann; Peter P Lee
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

Review 9.  Recycling the Purpose of Old Drugs to Treat Ovarian Cancer.

Authors:  Mariana Nunes; Miguel Henriques Abreu; Carla Bartosch; Sara Ricardo
Journal:  Int J Mol Sci       Date:  2020-10-20       Impact factor: 5.923

10.  Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway.

Authors:  Nana Xu; Mengmeng Lu; Jiaxin Wang; Yujia Li; Xiaotian Yang; Xiajie Wei; Jiaoyang Si; Jingru Han; Xiaojuan Yao; Juanmei Zhang; Junqi Liu; Yanming Li; Hushan Yang; Dengke Bao
Journal:  BMC Cancer       Date:  2021-12-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.